STAT3 and hepatocellular carcinoma: In previous human studies, nuclear phospho-STAT3 (Tyr705) was immunoreactive in 37–67% of head and neck squamous cell carcinoma samples and 49.3% of hepatocellular carcinomas (HCC) [33].